Initiation: Biological (r)evolution
Abzena offers a range of key services and technologies that enable its customers to develop safer and more effective biological products. This provides stable but growing revenues today, with the potential to generate substantial future revenues from small royalties on successful commercialisation of products created with Abzena’s technologies. Six candidates are now in clinical development; most notable is Gilead’s simtuzumab with Phase II trials ongoing for NASH, PSC and IPF. We value Abzena at £95m (97.5p/share) on its services/royalty mix.Abzena is providing a range of complementary services and technologies for the selection, development and manufacture of biopharmaceuticals.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.